Announced details
Laryngeal and pharyngeal cancer. Administration in combination with radiotherapy.
The PMDA is the recipient of the clinical trial notification. A clinical trial network has been established with research groups at Kyoto Prefectural University of Medicine and others. Capital and personnel relationships have not been disclosed.
The PMDA is the Pharmaceuticals and Medical Devices Agency. No information beyond the summary stated in the filing has been disclosed regarding the research groups at Kyoto Prefectural University of Medicine and others.
The impact on results for the fiscal year ending December 2026 is minor
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Oncolytic virus Telomelysin (development code: OBP-301) |
| Counterparty | Pharmaceuticals and Medical Devices Agency (PMDA), research groups at Kyoto Prefectural University of Medicine, and others |
| Counterparty overview | The PMDA is the Pharmaceuticals and Medical Devices Agency. No information beyond the summary stated in the filing has been disclosed regarding the research groups at Kyoto Prefectural University of Medicine and others. |
| Relationship with the Company | The PMDA is the recipient of the clinical trial notification. A clinical trial network has been established with research groups at Kyoto Prefectural University of Medicine and others. Capital and personnel relationships have not been disclosed. |
| Launch date | Administration scheduled to begin in the first half of 2027 |
| Applicable area | Laryngeal and pharyngeal cancer. Administration in combination with radiotherapy. |
| Impact on Business Performance | The impact on results for the fiscal year ending December 2026 is minor |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To develop Telomelysin for laryngeal and pharyngeal cancer with the aim of preserving the vocal cords.